OKUR · OnKure Therapeutics, Inc. · Insider Trading
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed Aug 4, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-07 | Leverone Jason A. |
Chief Financial Officer |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
5,322 |
| 2026-08-07 | Jansen Valerie Malyvanh |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
22,350 |
| 2026-08-07 | Leverone Jason A. |
Chief Financial Officer |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
130,611 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Employee Stock Option (right to buy)
|
2,359 |
| 2026-08-07 | Hartley Dylan |
Chief Scientific Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/4th of the shares subject to the option vested on June 9, 2025 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
137,603 |
| 2026-08-07 | Phillips Andrew John |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
22,350 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Employee Stock Option (right to buy)
|
2,359 |
| 2026-08-07 | GREY MICHAEL G |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
22,350 |
| 2026-08-07 | Mathers Edward T |
10% Owner |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
22,350 |
| 2026-08-07 | Agresta Samuel |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
50,000 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Employee Stock Option (right to buy)
|
16,898 |
| 2026-08-07 | Hartley Dylan |
Chief Scientific Officer |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/4th of the shares subject to the option vested on June 9, 2025 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
137,603 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
150,000 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Employee Stock Option (right to buy)
|
8,449 |
| 2026-08-07 | Leverone Jason A. |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
5,322 |
| 2026-08-07 | Agresta Samuel |
Chief Medical Officer |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
131,396 |
| 2026-08-07 | Leverone Jason A. |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
130,611 |
| 2026-08-07 | Agresta Samuel |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
18,588 |
| 2026-08-07 | Hartley Dylan |
Chief Scientific Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
50,000 |
| 2026-08-07 | Leverone Jason A. |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Employee Stock Option (right to buy
|
5,781 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
1,485 |
| 2026-08-07 | Manke Isaac |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Stock Option (right to buy)
|
15,300 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
542,232 |
| 2026-08-07 | Leverone Jason A. |
Chief Financial Officer |
Other↓
Filing footnotes — Employee Stock Option (right to buy (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Employee Stock Option (right to buy
|
5,781 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
1,485 |
| 2026-08-07 | Ratcliffe Liam |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
22,350 |
| 2026-08-07 | Leverone Jason A. |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
50,000 |
| 2026-08-07 | Carruthers R Michael |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
22,350 |
| 2026-08-07 | Manke Isaac |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
1/4th of the shares subject to the option shall vest on February 24, 2027 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Stock Option (right to buy)
|
300,000 |
| 2026-08-07 | Agresta Samuel |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
131,396 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Employee Stock Option (right to buy)
|
8,449 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Employee Stock Option (right to buy)
|
16,898 |
| 2026-08-07 | Saccomano Nicholas A |
Director, President and CEO |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
542,232 |
| 2026-08-07 | Agresta Samuel |
Chief Medical Officer |
Other↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
18,588 |
| 2026-08-07 | Manke Isaac |
Director |
Other↓
Filing footnotes — Stock Option (right to buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Stock Option (right to buy)
|
15,300 |
| 2026-06-22 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026. |
Class A Common Stock
|
86 |
| 2026-06-22 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Includes 3,105 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026. |
Class A Common Stock
|
303 |
| 2026-06-04 | Phillips Andrew John |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-06-04 | Ratcliffe Liam |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
1,275 |
| 2026-06-04 | GREY MICHAEL G |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-06-04 | Jansen Valerie Malyvanh |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-06-04 | Carruthers R Michael |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-06-04 | Mathers Edward T |
10% Owner |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-04-01 | Leverone Jason A. |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
110,000 |
| 2026-04-01 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
330,000 |
| 2026-04-01 | Hartley Dylan |
Chief Scientific Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
110,000 |
| 2026-04-01 | Agresta Samuel |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
110,000 |
| 2026-03-31 | Ratcliffe Liam |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
1/36th of the shares subject to the option shall vest on April 30, 2026 and on the last day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Stock Option (right to buy)
|
15,300 |
| 2026-03-23 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
301 |
| 2026-03-23 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
86 |